Epidemiological descriptive study of drug-resistant tuberculosis in Paraná, Brazil
Abstract
Objective: to describe the sociodemographic and clinical-epidemiological profile of individuals affected by DR-TB and its geographic distribution in Paraná between 2019 and 2023. Method: an epidemiological descriptive study was conducted using data from the Information System on Special Treatments for Tuberculosis (SITE-TB). This analysis focused on DR-TB cases reported in Paraná, Brazil, between 2019 and 2023. Data were collected from SITE-TB and analyzed for sociodemographic and clinical variables. Descriptive and inferential statistical analyses, including chi-square and Fisher’s exact tests, were performed to explore associations between variables and treatment outcomes. Geographic data were analyzed to identify incidence rates across municipalities. Results: the study identified 419 DR-TB cases in Paraná, with a predominance of males (75.2%), primarily white individuals (51.3%), and an average age of 38.3 years. Most cases were new (85.7%) and pulmonary (95.3%). Primary resistance (75.9%) and monoresistance (71.1%) were common. The cure rate was 41.2%, and treatment outcomes were associated with resistance type and history of previous treatments. A visually heterogeneous pattern of case occurrence was observed. Conclusions: these results suggest that targeted public health measures and tailored treatment protocols could improve DR-TB management in the state of Paraná.
Downloads
References
Maciel ELN, Sanchez MN, Cruz AMD, Cravo Neto DB, Lima NVT. Brazil's Pivotal Moment in Public Health: Establishing the Interministerial Committee (CIEDDS) for the Elimination of Tuberculosis and Socially Determined Diseases. Rev Soc Bras Med Trop. 2024;57:e00601–2024. https://doi.org/10.1590/0037-8682-0597-2023.
World Health Organization. Global tuberculosis report 2022. Geneva: OMS; 2022. https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf?sequence=1.
Pan American Health Organization. Tuberculosis in the Americas. Regional Report 2021. Washington, D.C.: PAHO; 2023. https://doi.org/10.37774/9789275126493.
Brasil. Ministério da Saúde. Brasil Livre da Tuberculose: Plano Nacional pelo Fim da Tuberculose como Problema de Saúde Pública: estratégias para 2021-2025. Brasília: Ministério da Saúde, 2021. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/tuberculose/plano-nacional-pelo-fim-da-tuberculose-como-problema-de-saude-publica_-estrategias-para-2021-2925.pdf/view.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629-655. Epub 2022 Jan 19. Erratum in: Lancet. 2022 Oct 1;400(10358):1102. https://doi.org/10.1016/S0140-6736(21)02653-2.
Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect Dis Poverty. 2023 May 25;12(1):57. PMID: 37231463; https://doi.org/10.1186/s40249-023-01107-x.
Brasil. Ministério da Saúde. Boletim Epidemiológico. Brasília: Ministério da Saúde, 2023. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2023/boletim-epidemiologico-de-tuberculose-numero-especial-mar.2023/@@download/file.
Bartholomay P, Pinheiro RS, Johansen FDC, Oliveira SB de, Rocha MS, Pelissari DM, et al. Lacunas na vigilância da tuberculose drogarresistente: relacionando sistemas de informação do Brasil. Cad Saúde Pública [Internet]. 2020;36(5):e00082219. https://doi.org/10.1590/0102-311X00082219.
Limenh LW, Kasahun AE, Sendekie AK, Seid AM, Mitku ML, Fenta ET, et al. Tuberculosis treatment outcomes and associated factors among tuberculosis patients treated at healthcare facilities of Motta Town, Northwest Ethiopia: a five-year retrospective study. Sci. Rep. 2024;14(7695). https://doi.org/10.1038/s41598-024-58080-0.
World Health Organization. Consolidated guidelines on tuberculosis, Module 4: Treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. https://iris.who.int/handle/10665/365308.
Orfão NH, Andrade RL, Ruffino-Netto A, Silva LWF, Villa TCS, Seifert ML, et al. Influence of COVID-19 on the notification of drug-resistant pulmonary tuberculosis cases. BMC Infect Dis 23, 497 (2023). https://doi.org/10.1186/s12879-023-08463-x.
Fundação Oswaldo Cruz. Boletim Epidemiológico Tuberculose Drogaressistente, 2022. https://www.arca.fiocruz.br/bitstream/handle/icict/51964/boletim_epidemiologico_tuberculose.PDF?sequence=2&isAllowed=yhttps://www.arca.fiocruz.br/bitstream/handle/icict/51964/boletim_epidemiologico_tuberculose.PDF?sequence=2&isAllowed=y.
Paraná. Plano Estadual pelo Fim da Tuberculose como Problema de Saúde Pública 2022-2030. Paraná, 1ª edição; 2022. https://www.documentador.pr.gov.br/documentador/pub.do?action=d&uuid=@gtf-escriba-sesa@5864ac51-d97c-4478-99b3-9885c9c09aef.
Brasil. Ministério da Saúde. Guia de vigilância em saúde. Brasília: Ministério da Saúde; 2024. https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/t/tetano-acidental/publicacoes/guia-de-vigilancia-em-saude-6a-edicao.pdf/@@download/file.
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-Collected health Data (RECORD) Statement. PLoS Med. 2015;12(10):e1001885. https://doi.org/10.1371/journal.pmed.1001885.
Lima IB, Nogueira LMV, Guimarães RJ de PS e, Rodrigues ILA, André SR, Abreu PD, et al. Spatial patterns of multidrug-resistant tuberculosis: correlation with sociodemographic variables and type of notification. Rev Bras Enferm [Internet]. 2020;73:e20190845. https://doi.org/10.1590/0034-7167-2019-0845.
Bakula Z, Wuyep VB, Bartocha L, Vyazovaya A, Ikeh EI, Bielecki J, et al. Molecular snapshot of drug-resistant Mycobacterium tuberculosis strains from the Plateau State, Nigeria. PLoS One, 2022; 17(5): e0266837. https://doi.org/10.1371/journal.pone.0266837.
Noa-Suárez D, Vázquez-Balart L. Tuberculosis farmacorresistente en provincia Guantánamo, 2010-2019. Rev. inf. cient. [Internet]. 2021;100(4), http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1028-99332021000400009&lng=es.
Jacobs MG, Pinto Junior VL. Caracterização da tuberculose drogarresistente no Brasil, 2014. Epidemiol Serv Saúde [Internet]. 2019;28(3):e2018294. https://doi.org/10.5123/S1679-49742019000300014.
Santos MR, Lima LV, Silva IGP, Monteiro LRS, Cecilio HPM, Gil NLM, et al. Perfil clínico-epidemiológico das pessoas acometidas por HIV/aids, tuberculose e hanseníase no Paraná, Brasil, 2010-2019. Cien. Cuid. 2022;21. https://doi.org/10.4025/ciencuidsaude.v21i0.61725.
Macedo LR, Maciel ELN, Struchiner CJ. Factors associated with tuberculosis in persons deprived of liberty in Espírito Santo. Rev Saúde Pública [Internet]. 2020; 54:67. https://doi.org/10.11606/s1518-8787.2020054001818.
Bendiksen R, Ovesen T, Asfeldt AM, Halvorsen DS, Gravningen K. Use of video directly observed treatment for tuberculosis in Northern Norway. Tidsskr Nor Laegeforen. 2020 Jan 13;140(1). PMID: 31948218; https://doi.org/10.4045/tidsskr.19.0322.
Sultana ZZ, Hoque FU, Beyene J, Akhlak-Ul-Islam M, Khan MHR, Ahmed S, et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jan 11;21(1):51. https://dopi.org/10.1186/s12879-020-05749-2. Erratum in: BMC Infect Dis. 2021 Jan 20;21(1):86. PMID: 33430786; https://doi.org/10.1186/s12879-021-05799-0.
Silva DR, Mello FCDQ, Migliori GB. Efeitos da COVID-19 no controle da tuberculose: passado, presente e futuro. J. Bras. Pneumol. (Online). 2022: 48, e20220102. https://doi.org/10.36416/1806-3756/e20220102.
Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022 Sep 23;12:943545. PMID: 36211964; https://doi.org/10.3389/fcimb.2022.943545.
Savioli MTG, Morrone N, Santoro I. Resistência bacilar primária em tuberculose multidrogarresistente e fatores preditivos associados à cura, em um centro de referência da cidade de São Paulo. J Bras Pneumol. 2019;45(2):e20180075. https://doi.org/10.1590/1806-3713/e20180075.
Bhering M, Kritski A. Primary and acquired multidrug-resistant tuberculosis: Predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000-2016. Rev Panam Salud Publica. 2020 Dec 30;44:e178. PMID: 33417644; https://doi.org/10.26633/RPSP.2020.178.
Wang SF, Zhou Y, Pang Y, Zheng HW, Zhao YL. Prevalence and Risk Factors of Primary Drug-Resistant Tuberculosis in China. Biomed Environ Sci. 2016 Feb;29(2):91-8. PMID: 27003166. https://doi.org/10.3967/bes2016.010.
Safaev K, Parpieva N, Liverko I, Yuldashev S, Dumchev K, Gadoev J, et al. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018. Int J Environ Res Public Health. 2021 Apr 27;18(9):4663. PMID: 33925705; https://doi.org/10.3390/ijerph18094663.
Zhao B, Liu C, Fan J, Ma A, He W, Hu Y, et al. Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China. Microbiol Spectr. 2022 Oct 26;10(5):e0240521. Epub 2022 Oct 10. PMID: 36214695; https://doi.org/10.1128/spectrum.02405-21.
Vanino E, Granozzi B, Akkerman OW, Munoz-Torrico M, Palmieri F, Seaworth B, et al. Update of drug-resistant tuberculosis treatment guidelines: A turning point. Int J Infect Dis. 2023 May;130 Suppl 1:S12-S15. Epub 2023 Mar 12. PMID: 36918080. https://doi.org/10.1016/j.ijid.2023.03.013.
Lima LV, Pavinati G, Ohta AA, Gil NLM, Moura DRO, Magnabosco GT. Distribution of tuberculosis cases in the state of Paraná: an ecological study, Brazil, 2018-2021. Epidemiol Serv Saude. 2023 Jun 19;32(2):e2022586. PMID: 37341230; https://doi.org/10.1590/S2237-96222023000200010.
Copyright (c) 2025 Ciência, Cuidado e Saúde
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
